Phase 3

News and Video Search Results

News coverage

PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness

GlobeNewswire 16 Apr 2024

· Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates immediate need for direct..

Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
GlobeNewswire 16 Apr 2024
Global Corneal Implants Market Size To Worth USD 763.0 Million By 2033 | CAGR Of 5.9%
GlobeNewswire 16 Apr 2024
OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective
GlobeNewswire 16 Apr 2024
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Accesswire 16 Apr 2024

0 shares 2 views

You might like

Phase 3 media coverage

Tonusd - A Unique Digital Asset Backed By the Power of Liquidity Provider

Accesswire 16 Apr 2024

*SINGAPORE, SINGAPORE / ACCESSWIRE / April 16, 2024 / *TonUSD is an ambitious cryptocurrency project aimed at creating a..

Truth Social to Launch Streaming Platform
GlobeNewswire 16 Apr 2024
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
GlobeNewswire 16 Apr 2024
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
GlobeNewswire 16 Apr 2024
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
GlobeNewswire 16 Apr 2024

Advertisement

More coverage

GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents

GlobeNewswire 15 Apr 2024

*Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 15, 2024* - *GENFIT (Nasdaq and Euronext:..

New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
GlobeNewswire 15 Apr 2024
Marinus plummets 78% as phase 3 interim analysis of ganaxolone disappoints
SeekingAlpha 15 Apr 2024
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
GlobeNewswire 15 Apr 2024
Redemption Date Announced for Warrants
GlobeNewswire 15 Apr 2024